


**AMENDMENTS TO THE CLAIMS:**


This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

1. (Currently Amended) A polycyclic (pyrimidine-2,4(1H, 3H)-dione) with functionalized alkyl groups in the 1-, 3-, or both positions with the general structures Ia and Ib,



(Ia)



(Ib)

where:

R<sup>1</sup> is hydrogen, methyl, or ethyl

R<sup>2</sup> is hydrogen or methyl

R<sup>3</sup> is mercapto or hydroxyaminoacylalkylthio (-SAlkCONHOH)

Alk is C<sub>1</sub>-C<sub>5</sub> branched or unbranched alkyl (C<sub>4</sub>-C<sub>5</sub>, branched and unbranched)

R<sup>4</sup> [R4] is hydrogen, benzyl, or phenyl

n is 0, 1 or 2,

Alk\* is C<sub>2</sub>-C<sub>12</sub> branched or unbranched alkylene, {C<sub>2</sub>-C<sub>12</sub>; branched or unbranched, with the exception of 3-methylpropylene [-CH<sub>2</sub>-CH<sub>2</sub>-CH(CH<sub>3</sub>)-]}

X is mercapto or hydroxyaminoacylalkylthio (-SAlkCONHOH)

A is an annealed benzene ring


or

a 2,3-annealed thiophene ring, which may in the 4,5-positions be substituted with methyl groups or annealed with a cyclopentene, cyclohexene, or cycloheptene rings,


$R^5$  is hydrogen, 6-methyl, 8-methyl, 6-fluoror, 6-choloro, 6-bromo, 6-methylthio, or 6,7-dimethoxy,

as well as the tautomers and pharmacologically relevant salts of these compounds.

2. (Currently Amended) A chinazolin-2,4(1H,3H)-dione with functionalized Chinazolin 2,4(1H,3H)-diones with functionalized alkyl groups in the 1-, 3-, or both positions according to as described in Claim 1 with for the general structures IIa and IIb



(IIa)



(IIb)

where with  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ , Alk, Alk\*, n, and X are defined as in Claim 1, including their tautomers and pharmacologically relevant salts.

3. (Cancelled)

4. (Cancelled)

5. (Currently Amended) A pharmaceutical composition comprising  
preparation containing one or more compounds of in claim 1 and an inert  
carrier, as well as commonly used filler and inert ingredients, and binders.

6. (Cancelled)

7. (New) A method of inhibiting collagenase/MMP activities in a mammal comprising administering to the mammal in need thereof an effective amount of one or more compounds of claim 1.

8. (New) A method of inhibiting tumor metastasis and invasion in a mammal comprising administering to the mammal in need thereof an effective amount of one or more compounds of claim 1.

9. (New) A method of treating UV-induced erythema in a mammal comprising administering to the mammal in need thereof an effective amount of one or more compounds of claim 1.

10. (New) A method of treating rheumatic diseases in a mammal comprising administration to the mammal in need thereof an effective amount of one or more compounds of claim 1.